Clinical Trials on Invasive Bladder Cancer Stage II

Total 5474 results

Rigshospitalet, Denmark

Recruiting

Diagnosing Ovarian Cysts - the DOC Study

Ovarian Cysts | Ovarian Neoplasms | Ovarian Cancer | Ovarian Cancer Stage

Denmark
Amgen

Terminated

Safety Study of AMG 228 to Treat Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Oncology | Tumors | Advanced Malignancy | Oncology Patients | Transitional Cell Carinoma of Bladder

Belgium, France, United States, Germany, Australia
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Extensive Stage Lung Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

KRAS Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Recruiting

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Lymph Nodes

United States
University of Washington
National Cancer Institute (NCI)

Completed

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
National Cancer Institute (NCI)

Completed

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States, Peru
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

Stage 0 Cervical Cancer | High-grade Squamous Intraepithelial Lesion
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
Carisma Therapeutics Inc

Active, not recruiting

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Adenocarcinoma | Stomach Neoplasms | Cancer | Breast Cancer | Head and Neck Cancer | Carcinoma, Hepatocellular | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Carcinoma, Ovarian Epithelial | Carcinoma, Transitional Cell | Breast Neoplasm | Prostate Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer and other conditions

United States
National Cancer Institute (NCI)

Terminated

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Large Cell Lung Carcinoma | Bronchioloalveolar Lung Carcinoma

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya

Cervix Cancer | Cervix Intraepithelial Neoplasia Grade 3 | Cervix; Intraepithelial Neoplasia, Grade I | Cervix; Intraepithelial Neoplasia, Grade II

Kenya
Daping Hospital and the Research Institute of Surgery...

Active, not recruiting

PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy

Surgery | Esophageal Squamous Cell Carcinoma

China
German Cancer Research Center
University Hospital Heidelberg

Recruiting

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma (IntenSify)

Pancreatic Cancer | Pancreatic Adenocarcinoma | CYP3A Inhibitor | Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm

Germany
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Exelixis

Active, not recruiting

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8

United States
University of Nebraska

Recruiting

Integrated Cancer Repository for Cancer Research (iCaRe2)

Melanoma | Sarcoma | Kidney Cancer | Leukemia | Breast Cancer | Laryngeal Cancer | Hypopharyngeal Cancer | Nasopharyngeal Cancer | Multiple Myeloma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Ovarian Cancer | Lynch Syndrome | Lung Cancer | Rectal Cancer | Prostate Cancer | Gastrointestinal... and other conditions

United States
Massive Bio, Inc.

Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Melanoma | Follicular Lymphoma | Carcinoma | Myelodysplastic Syndromes | Leukemia | Cancer | Breast Cancer | Myeloproliferative Disorders | Glioblastoma | Myelofibrosis | Ovarian Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Neuroendocrine Tumors | Non Small Cell Lung Cancer | COVID | Non Hodgkin Lymphoma | Cholang... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy

Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Suspended

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8

United States
Saint Petersburg State University, Russia

Withdrawn

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

Russian Federation
University of California, San Francisco
National Cancer Institute (NCI)

Terminated

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Dr Jean Yannis PERENTES

Recruiting

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Mesothelioma, Malignant | Carcinoma Breast Stage IV

Switzerland
Northwestern University
National Cancer Institute (NCI)

Recruiting

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Active, not recruiting

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

EGFR Exon 20 Mutation | ERBB2 Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Novartis; Prostate Cancer Clinical Trials Consortium

Completed

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7 | Prostate Carcinoma Metastatic in the Bone

United States
Roswell Park Cancer Institute
GlaxoSmithKline

Active, not recruiting

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Seagen Inc.

Terminated

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Cervical Cancer | Ovarian Cancer | Peripheral T-cell Lymphoma | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Classical Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma | Cutaneous Melanoma | Gastroesophageal Junction...

United States, Spain, Canada, United Kingdom, France, Italy
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Melanoma | Sarcoma | Breast Cancer | Solid Tumor | Prostate Cancer | Bladder Cancer | Head and Neck Squamous Cell Carcinoma | Cutaneous T-Cell Lymphoma | Renal Cancer | Merkel Cell Carcinoma | Testicular Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
Seoul National University Hospital

Completed

Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy (SDLNOC)

Lymph Node Metastases | Ovarian Cancer Stage IV

Korea, Republic of
Bijan Najafi, PhD
Orthotic Holdings, Inc.

Completed

OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO

Diabetes | Cancer | Arthritis | Parkinson's Disease | Peripheral Arterial Disease | End Stage Renal Failure on Dialysis | Accidental Falls | Fall Due to Loss of Equilibrium | High Risk of Falls Due to Mobility Limitation

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer AJCC v6 and v7

United States
Celldex Therapeutics
Merck Sharp & Dohme LLC

Completed

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Melanoma | Follicular Lymphoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Fallopian Tube Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | ... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
23andMe, Inc.

Active, not recruiting

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Clear Cell Renal Cell Carcinoma | Fallopian Tube Cancer | Solid Tumor | Neuroendocrine Tumors | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma | Extensive-stage Small-cell Lung Cancer | MSI-H Cancer | Cancer With A High Tumor Mutational Burden

United States, Canada
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
Sun Yat-sen University

Recruiting

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Hepatocellular Carcinoma | Pulmonary Metastases | Bevacizumab | Liver Cancer Stage IV | Cryoablation | Cadonilimab

China
Centre Francois Baclesse

Completed

Search for Predictors of Therapeutic Response in Ovarian Carcinoma (miRSa)

Fallopian Tube Cancer | Carcinoma of the Ovary | Peritoneal Serous-type Advanced Stage

France
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma

United States
Taproot Health

Recruiting

The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)

Melanoma | Sarcoma | Kidney Cancer | Adenocarcinoma | Renal Cell Carcinoma | Cervical Cancer | Acute Myeloid Leukemia | Stomach Cancer | Breast Cancer | Head and Neck Neoplasms | Nasopharyngeal Carcinoma | Glioblastoma | Astrocytoma | Multiple Myeloma | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer and other conditions

United States
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
University of Washington
National Institute of Nursing Research (NINR)

Completed

Improving Clinician Communication Skills (ICCS) (ICCS)

End Stage Liver Disease | Chronic Obstructive Pulmonary Disease (COPD) | Advanced Cancer | Congestive Heart Failure | Restrictive Lung Disease

United States
National Cancer Institute (NCI)

Recruiting

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Stage IV Renal Cell Cancer AJCC v8 | Metastatic Papillary Renal Cell Carcinoma

United States

Clinical Trials on Invasive Bladder Cancer Stage II

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations